Edition:
India

Onconova Therapeutics Inc (ONTX.OQ)

ONTX.OQ on NASDAQ Stock Exchange Capital Market

0.61USD
12:52am IST
Change (% chg)

$0.01 (+1.33%)
Prev Close
$0.60
Open
$0.66
Day's High
$0.68
Day's Low
$0.60
Volume
332,945
Avg. Vol
66,932
52-wk High
$2.83
52-wk Low
$0.60

Select another date:

Thu, Apr 19 2018

BRIEF-Onconova Presents Data On Dual Inhibitor Of Cdk4/6 + Ark5 At American Association For Cancer Research 2018 Annual Meeting

* ONCONOVA PRESENTS DATA ON DUAL INHIBITOR OF CDK4/6 + ARK5 AT AMERICAN ASSOCIATION FOR CANCER RESEARCH 2018 ANNUAL MEETING

BRIEF-Onconova Therapeutics Says Offering Up To 18.5 Mln Units Of Common Stock, Warrants

* ONCONOVA THERAPEUTICS - OFFERING UP TO 18.5 MILLION UNITS (UNIT CONSISTING OF ONE SHARE OF COMMON STOCK AND ONE WARRANT) Source text (https://bit.ly/2J0SqAg) Further company coverage:

BRIEF-Onconova Therapeutics Reports Full-Year 2017 Results

* ONCONOVA THERAPEUTICS, INC. REPORTS BUSINESS HIGHLIGHTS AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Onconova Therapeutics Announces License Agreement With Pint Pharma To Commercialize Rigosertib

* ONCONOVA THERAPEUTICS ANNOUNCES LICENSE AGREEMENT WITH PINT PHARMA TO COMMERCIALIZE RIGOSERTIB FOR TREATMENT OF MYELODYSPLASTIC SYNDROMES IN LATIN AMERICA

BRIEF-683 Capital Management Reports 21.8 Pct Stake In Onconova Therapeutics

* 683 CAPITAL MANAGEMENT LLC REPORTS 21.8 PERCENT STAKE IN ONCONOVA THERAPEUTICS INC AS OF FEB 8 - SEC FILING

BRIEF-Onconova Says Moving Forward With Pivotal Late-Stage Trial

* ONCONOVA MOVING FORWARD WITH PHASE 3 INSPIRE PIVOTAL TRIAL WITH INCREASED SAMPLE SIZE FOLLOWING PROMISING INTERIM ANALYSIS

BRIEF-Onconova Therapeutics Says Entered Into Cooperative Research And Development Agreement With NCI

* ONCONOVA THERAPEUTICS SAYS ENTERED INTO COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT WITH NATIONAL CANCER INSTITUTE

BRIEF-Onconova Therapeutics Announces License And Collaborative Development Agreement With Hanx Biopharma

* ONCONOVA THERAPEUTICS ANNOUNCES LICENSE AND COLLABORATIVE DEVELOPMENT AGREEMENT WITH HANX BIOPHARMACEUTICALS FOR ON 123300, A DUAL INHIBITOR OF CDK4/6 + ARK5

BRIEF-Onconova Therapeutics files for mixed shelf offering of upto $84.5 mln

* Onconova Therapeutics Inc files for mixed shelf offering of upto $84.5 million- SEC filing‍​ Source text: (http://bit.ly/2AiGwl1) Further company coverage:

BRIEF-Onconova Therapeutics announces data on improved formulation of Rigosertib and next-generation CDK4/6 inhibitor

* Onconova Therapeutics announces data on improved formulation of Rigosertib and next-generation CDK4/6 inhibitor at 2017 American Association Of Pharmaceutical Scientists annual meeting Source text for Eikon: Further company coverage:

Select another date: